<DOC>
	<DOCNO>NCT02362230</DOCNO>
	<brief_summary>Evaluating safety efficacy Icotinib administer 2-month treatment , patient metastatic triple-negative breast cancer receive least two prior treatment .</brief_summary>
	<brief_title>Evaluation Icotinib Metastatic Triple-negative Breast Cancer After Second-line Therapy</brief_title>
	<detailed_description>This phase II , multi-center study . Sixty-seven patient plan enrol . All patient receive Icotinib 125 mg BID administer 8 week . Patients complete response , partial response stable disease time may continue treat base physician discretion . Follow require resolution stabilization treatment-related toxicity , patient stable disease objective response must also continue evaluation survive .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Age 18 year old ECOG 0 1 Primary metastatic tumor onfirmed triple negative Measurable disease per RECIST version 1.1 normal organ function , include bone marrow function , renal function , liver function , cardiac function Two prior chemotherapy sign date informed consent form Life expectancy least 12 week Pregnant breast feed ECOG score â‰§2 Uncontrolled medical problem Hepatic , renal , bone marrow dysfunction detail Concurrent malignancy history malignancy within last five year except noted Patients unable unwilling comply program requirement</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>